1. A combination vaccine containing a genetically detoxified pertussis toxin and one or more additional antigens selected from IPV (inactivated polio vaccine), HBsAg (hepatitis B virus surface antigen) and Hib (Haemophilus influenzae type b), characterized in that it is genetically detoxified pertussis toxin is not treated with formaldehyde or glutaraldehyde. 2. The combination vaccine of claim 1, wherein the pertussis toxin is not treated with a cross-linking aldehyde agent. The combination vaccine according to claim 1, wherein the pertussis toxin is not treated with a crosslinking agent. Combination vaccine containing antigens of B. pertussis PT (pertussis toxoid), FHA (filament hemagglutinin) and pertactin, characterized in that at least two of the B. pertussis antigens are not treated with formaldehyde or glutaraldehyde, provided that if PT is not processed with a crosslinking agent, PT is a genetically detoxified pertussis toxin. 5. The combination vaccine of claim 4, wherein at least two of the B. pertussis antigens are not treated with a cross-linking aldehyde agent. The combination vaccine of claim 4, wherein at least two of the B. pertussis antigens are not treated with a cross-linking agent. A combination vaccine containing an aluminum salt adjuvant and at least two non-cross-linked B. pertussis antigens selected from PT, FHA and pertactin, provided that any PT is genetically detoxified. 8. The combination vaccine of claim 7, wherein the AI concentration is less than 1 mg / ml. The combination vaccine of claim 7, wherein the vaccine further comprises a TLR4 agonist (Toll-like receptor 4). The combination vaccine of claim 9, wherein the vaccine comprises AS04 as an adjuvant. Combination vaccine containing at least1. Комбинированная вакцина, содержащая генетически детоксифицированный коклюшный токсин и один или более чем один дополнительный антиген, выбранный из IPV (инактивированной полиомиелитной вакцины), HBsAg (поверхностный антиген вируса гепатита В) и
